The proteasome is responsible for mediating intracellular protein degradation and
regulating cellular function with impact on tumor and immune effector cell biology. The …

The synchronous functioning and quality control of organelles ensure cell survival and
function and are essential for maintaining homeostasis. Prolonged exposure to stressors …

Simple Summary Bone cancer has seen minimal benefits in therapeutic options in the past
30 years. Proteasome inhibitors present a new avenue of research for the treatment of bone …

Despite the liver being the primary site for clearance of xenobiotics utilizing a myriad of
mechanisms ranging from cytochrome P450 enzyme pathways, glucuronidation, and biliary …

Preclinical and clinical investigation on proteasome as a druggable target in cancer has led
to the development of proteasome inhibitors (PIs) with different pharmacodynamic and …

Abstract Ecto-5'-nucleotidase (CD73), encoded by the NT5E gene, mediates tumor
immunosuppression and has been targeted for the development of new anticancer drugs …

Targeting the proteome has become an increasingly important therapeutic strategy across a
variety of hematologic malignancies, but especially in those disease derived from …

Background Proteasome inhibitor drugs have provided a major breakthrough in the
treatment of multiple myeloma and other hematological malignancies. Currently, there are …

Endoplasmic reticulum stress (ER stress) is characterized by the accumulation of misfolded
and unfolded proteins in the ER lumen. To mitigate the imbalanced ER protein-folding …

Carfilzomib is a second-generation, covalent, and irreversible proteasome inhibitor
approved as a monotherapy and used in combinations for the treatment of patients with …